Trial Profile
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ArtStiff
- Sponsors Daiichi Sankyo Europe
- 18 Dec 2021 The trial has been completed in Italy, according to the European Clinical Trials Database record.
- 17 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
- 03 Jul 2012 Planned number of patients changed from 318 to 350 as reported by EudraCT.